Osilodrostat Resolves Most Physical Signs of Cushing’s Disease
SAN DIEGO — Osilodrostat (Isturisa) improved many physical features associated with Cushing’s disease, according to additional findings from the phase III LINC-3 study. Among 137 adults with Cushing’s disease, a 39.5% improvement in central obesity scores was observed from baseline to week 72 with osilodrostat, reported Alberto Pedroncelli, MD, PhD, of Recordati AG in Basel, […]